The rapid rise in demand for GLP-1 injectable drugs is set to drive growth for SCHOTT Glass India, which plans to double its revenue and profitability in the next three to three-and-a-half years.

The German specialty glass manufacturer, a 100% subsidiary of SCHOTT AG, Germany, is also preparing for an additional ₹150-crore investment in its Jambusar facility in Gujarat to expand capacity and strengthen quality systems. Advertisement

“The GLP-1 drug market is growing at around 30-35% annually, and nearly three-fourths of this demand is for injectables,” Pawan Kumar Shukla, President and Managing Director of SCHOTT Glass India told Business Today. “We anticipated this trend early and invested in tubing for syringes and cartridges used in pre-filled syringes. Our current capacity can handl

See Full Page